Ceftriaxone susceptibility of oxacillin-susceptible Staphylococcus aureus from patients with prosthetic joint infection

Kerryl E. Greenwood-Quaintance, Peggy Kohner, Douglas R. Osmon, Abinash Virk, Robin Patel

Research output: Contribution to journalArticle

3 Scopus citations


Ceftriaxone is used to treat oxacillin-susceptible S. aureus (OSSA) prosthetic joint infection (PJI). Susceptibility of ceftriaxone against OSSA has been questioned. Ceftriaxone susceptibility was determined against 100 PJI OSSA isolates. Ceftriaxone MIC<inf>90</inf>/MIC<inf>50</inf> were 8/4 and 4/3μg/mL by broth microdilution and Etest, respectively. Ceftriaxone susceptibility is inferable by oxacillin susceptibility.

Original languageEnglish (US)
Pages (from-to)177-178
Number of pages2
JournalDiagnostic Microbiology and Infectious Disease
Issue number2
StatePublished - Jun 1 2015



  • Ceftriaxone
  • Oxacillin-susceptible Staphylococcus aureus
  • Prosthetic joint infection

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this